However, concerns have been raised about the possibility of serious adverse cardiovascular events following sclerostin inhibition (Pietrzyk et al., 2017; Bovijn et al., 2020; Kawaguchi, 2020), and anti-sclerostin antibodies are generally contraindicated in case of a history of myocardial infarction or stroke (Krupa et al., 2023). Here, SOST is linked to myocardial infarction.